JP2014530602A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530602A5 JP2014530602A5 JP2014534724A JP2014534724A JP2014530602A5 JP 2014530602 A5 JP2014530602 A5 JP 2014530602A5 JP 2014534724 A JP2014534724 A JP 2014534724A JP 2014534724 A JP2014534724 A JP 2014534724A JP 2014530602 A5 JP2014530602 A5 JP 2014530602A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- lipid
- nucleic acid
- particle
- item
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161543700P | 2011-10-05 | 2011-10-05 | |
| US61/543,700 | 2011-10-05 | ||
| US201261599238P | 2012-02-15 | 2012-02-15 | |
| US61/599,238 | 2012-02-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014530602A JP2014530602A (ja) | 2014-11-20 |
| JP2014530602A5 true JP2014530602A5 (enExample) | 2015-09-10 |
Family
ID=48044157
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534724A Pending JP2014530602A (ja) | 2011-10-05 | 2012-10-04 | アルデヒドデヒドロゲナーゼをサイレンシングするための組成物および方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8999950B2 (enExample) |
| EP (1) | EP2764007A4 (enExample) |
| JP (1) | JP2014530602A (enExample) |
| KR (1) | KR20140097143A (enExample) |
| CN (1) | CN104114571A (enExample) |
| AU (2) | AU2012318249B2 (enExample) |
| CA (1) | CA2850792A1 (enExample) |
| HK (1) | HK1200837A1 (enExample) |
| RU (1) | RU2014117690A (enExample) |
| WO (1) | WO2013052677A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ588583A (en) | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| US8283333B2 (en) | 2009-07-01 | 2012-10-09 | Protiva Biotherapeutics, Inc. | Lipid formulations for nucleic acid delivery |
| PL3338765T3 (pl) | 2009-12-01 | 2019-06-28 | Translate Bio, Inc. | Pochodna steroidowa dla dostarczania mrna w ludzkich chorobach genetycznych |
| WO2012000104A1 (en) | 2010-06-30 | 2012-01-05 | Protiva Biotherapeutics, Inc. | Non-liposomal systems for nucleic acid delivery |
| US8853377B2 (en) | 2010-11-30 | 2014-10-07 | Shire Human Genetic Therapies, Inc. | mRNA for use in treatment of human genetic diseases |
| DK3336082T3 (da) | 2011-06-08 | 2020-04-27 | Translate Bio Inc | Spaltelige lipider |
| PT2717893T (pt) | 2011-06-08 | 2019-08-20 | Translate Bio Inc | Composições de nanopartículas lipídicas e métodos para transferência de arnm |
| ES2762873T3 (es) | 2012-03-29 | 2020-05-26 | Translate Bio Inc | Lípidos catiónicos ionizables |
| EP3865123A1 (en) | 2012-03-29 | 2021-08-18 | Translate Bio, Inc. | Lipid-derived neutral nanoparticles |
| WO2013185069A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| WO2013185067A1 (en) | 2012-06-08 | 2013-12-12 | Shire Human Genetic Therapies, Inc. | Nuclease resistant polynucleotides and uses thereof |
| EP2968586B1 (en) | 2013-03-14 | 2018-07-25 | Translate Bio, Inc. | Cftr mrna compositions and related methods and uses |
| ES2981185T3 (es) | 2013-03-14 | 2024-10-07 | Translate Bio Inc | Métodos para la purificación de ARN mensajero |
| CA2928040A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Cns delivery of mrna and uses thereof |
| US11224642B2 (en) | 2013-10-22 | 2022-01-18 | Translate Bio, Inc. | MRNA therapy for argininosuccinate synthetase deficiency |
| WO2015061467A1 (en) | 2013-10-22 | 2015-04-30 | Shire Human Genetic Therapies, Inc. | Lipid formulations for delivery of messenger rna |
| MX2016005239A (es) | 2013-10-22 | 2016-08-12 | Shire Human Genetic Therapies | Tratamiento con acido ribonucleico mensajero para la fenilcetonuria. |
| JP6571679B2 (ja) | 2014-04-25 | 2019-09-04 | トランスレイト バイオ， インコーポレイテッド | メッセンジャーｒｎａの精製方法 |
| US10022455B2 (en) | 2014-05-30 | 2018-07-17 | Translate Bio, Inc. | Biodegradable lipids for delivery of nucleic acids |
| CA2952824C (en) | 2014-06-24 | 2023-02-21 | Shire Human Genetic Therapies, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| CA2953265C (en) | 2014-07-02 | 2023-09-26 | Shire Human Genetic Therapies, Inc. | Encapsulation of messenger rna |
| MA56412A (fr) | 2014-12-05 | 2022-05-04 | Translate Bio Inc | Thérapie par l'arn messager pour le traitement des maladies articulaires |
| WO2016149508A1 (en) | 2015-03-19 | 2016-09-22 | Shire Human Genetic Therapies, Inc. | Mrna therapy for pompe disease |
| WO2016183366A2 (en) * | 2015-05-12 | 2016-11-17 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing expression of hepatitis d virus rna |
| CN108473969B9 (zh) | 2015-10-14 | 2024-08-23 | 川斯勒佰尔公司 | 用于增强生产的rna相关酶的修饰 |
| US10358647B2 (en) | 2015-12-13 | 2019-07-23 | Nitto Denko Corporation | siRNA structures for high activity and reduced off target |
| AU2018224326B2 (en) | 2017-02-27 | 2024-01-04 | Translate Bio, Inc. | Novel codon-optimized CFTR mRNA |
| EP3483269A1 (en) * | 2017-11-13 | 2019-05-15 | Silence Therapeutics GmbH | Products and compositions |
| MX2019013752A (es) | 2017-05-16 | 2020-07-20 | Translate Bio Inc | Tratamiento de la fibrosis quística mediante el suministro de arnm que codifica cftr optimizado en codones. |
| EP3735461A1 (en) * | 2017-11-13 | 2020-11-11 | Silence Therapeutics GmbH | Nucleic acids for inhibiting expression of aldh2 in a cell |
| WO2019143621A1 (en) * | 2018-01-16 | 2019-07-25 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting aldh2 expression |
| AU2019227510B2 (en) | 2018-03-02 | 2026-02-12 | Novo Nordisk A/S | Compositions and methods for inhibiting GYS2 expression |
| CN118421617A (zh) | 2018-08-24 | 2024-08-02 | 川斯勒佰尔公司 | 用于纯化信使rna的方法 |
| CN113166783B (zh) | 2018-10-09 | 2024-10-11 | 不列颠哥伦比亚大学 | 包含无有机溶剂和去污剂的转染活性囊泡的组合物和系统以及与之相关的方法 |
| EP3883592A1 (en) | 2018-11-21 | 2021-09-29 | Translate Bio, Inc. | Treatment of cystic fibrosis by delivery of nebulized mrna encoding cftr |
| WO2020206350A1 (en) * | 2019-04-04 | 2020-10-08 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for inhibiting gene expression in the central nervous system |
| WO2021055609A1 (en) | 2019-09-20 | 2021-03-25 | Translate Bio, Inc. | Mrna encoding engineered cftr |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG190613A1 (en) * | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| US7404969B2 (en) * | 2005-02-14 | 2008-07-29 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
| WO2007051303A1 (en) * | 2005-11-02 | 2007-05-10 | Protiva Biotherapeutics, Inc. | MODIFIED siRNA MOLECULES AND USES THEREOF |
| JP2010519203A (ja) * | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
| NZ588583A (en) * | 2008-04-15 | 2012-08-31 | Protiva Biotherapeutics Inc | Novel lipid formulations for nucleic acid delivery |
| US20110071208A1 (en) * | 2009-06-05 | 2011-03-24 | Protiva Biotherapeutics, Inc. | Lipid encapsulated dicer-substrate interfering rna |
| AU2010260148A1 (en) * | 2009-06-15 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Lipid formulated dsRNA targeting the PCSK9 gene |
| US8236943B2 (en) * | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
| WO2011011447A1 (en) * | 2009-07-20 | 2011-01-27 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing ebola virus gene expression |
-
2012
- 2012-10-04 JP JP2014534724A patent/JP2014530602A/ja active Pending
- 2012-10-04 WO PCT/US2012/058770 patent/WO2013052677A1/en not_active Ceased
- 2012-10-04 KR KR1020147011617A patent/KR20140097143A/ko not_active Withdrawn
- 2012-10-04 HK HK15101352.3A patent/HK1200837A1/xx unknown
- 2012-10-04 CA CA2850792A patent/CA2850792A1/en not_active Abandoned
- 2012-10-04 EP EP12838796.6A patent/EP2764007A4/en not_active Withdrawn
- 2012-10-04 US US14/349,619 patent/US8999950B2/en not_active Expired - Fee Related
- 2012-10-04 CN CN201280059878.1A patent/CN104114571A/zh active Pending
- 2012-10-04 AU AU2012318249A patent/AU2012318249B2/en not_active Expired - Fee Related
- 2012-10-04 RU RU2014117690/10A patent/RU2014117690A/ru not_active Application Discontinuation
-
2016
- 2016-03-29 AU AU2016201913A patent/AU2016201913A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014117690A (ru) | Композиции и способы для сайленсинга альдегид-дегидрогеназы | |
| JP2011516094A5 (enExample) | ||
| EP3201338B1 (en) | Compositions and methods for silencing hepatitis b virus gene expression | |
| JP2017536092A5 (enExample) | ||
| US20210047640A1 (en) | Compositions and methods for treating hypertriglyceridemia | |
| JP2022111231A (ja) | メッセンジャーｒｎａを送達するための組成物及び方法 | |
| JP2012531469A5 (enExample) | ||
| JP5766188B2 (ja) | 固形腫瘍に治療剤を送達するための脂質製剤 | |
| TW201718856A (zh) | 用於使b型肝炎病毒基因表現沈默之組合物及方法 | |
| WO2016071857A1 (en) | Compositions and methods for silencing ebola virus expression | |
| CA2750561A1 (en) | Compositions and methods for silencing apolipoprotein c-iii expression | |
| JP2009507876A5 (enExample) | ||
| US9035039B2 (en) | Compositions and methods for silencing SMAD4 | |
| JP2009513151A5 (enExample) | ||
| WO2016183366A2 (en) | Compositions and methods for silencing expression of hepatitis d virus rna | |
| JP2022000479A (ja) | インフュージョンリアクションを改善するための方法 | |
| CN120957708A (zh) | 用于反义寡核苷酸递送的脂质纳米粒制剂 | |
| WO2024199144A1 (en) | Novel reagent for mitigating lnp toxicity | |
| US20160076035A1 (en) | Compositions and methods for silencing marburg virus gene expression | |
| HK1234102B (en) | Compositions and methods for silencing hepatitis b virus gene expression |